Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class...
Volume fell today along with the stock, which is a good sign as volume should follow the stock.
Major support is around the corner, so there is a good chance that the stock will bounce back.
The overall, bullish trend has been strong.
I like the consolidation over the past 2 weeks or so and the MACD cross that is about to happen. The price tested the .23 fib level several times but so far it has acted as resistance.
I would like to see a break of $2.79 with high relative volume to take a swing position.
Targets: $2.94, $3.05. $3.17, $3.34 and $3.55
Follow the trend!
PALISADE Phase 3 Clinical Program for PH94B:
The PALISADE Phase 3 clinical program has been initiated to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray with a unique mechanism of action, working...
Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average price target is $7.00 with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 123.64% change from the last price of $3.13.
All,
I think you see some erie similarities and the extreme HL aka bullish moves and could form ascend bullish triangle here. Earnings is June 29th being bio may or may not matter more than likely nuetral. Regardless solid setup here either way if it pops here and holds the ascend tri / a fall I believe would just set up for the exact same thing which wold be a...
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III...
Contextual immersion trading strategy idea.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS).
The demand for shares of the company looks higher than the supply.
This and...
Why VistaGen Therapeutics Stock Soared yesterday
The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday.
Why bullish?
Tsai really likes the potential for VistaGen's lead ...
* This is not financial advice. This is my non-expert opinion. *
Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to...
NASDAQ:VTGN This isn't financial advice (hell no). I like this stock. The company has potential. This is a nice buying opportunity in non-expert opinion. So, I'm scooping up before their phase 3 trials.
Possible breakout from ascending triangle within wave count. With correction to around $1.ish (buy on possitive divergence) prior to progression of wave 3.
